Shine-On BioMedical Co., Ltd.
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
The company’s pipeline features novel therapeutic candidates, such as precision-engineered exosomes for targeted drug delivery and nanometer-scale trispecific antibodies that engage T cells. These next-generation biologics are designed to improve the spec
The content above was translated by Ai
Founded Year
2021
Unified Business No.
90841519
Status
Active
Number of Employees
0
Total Paid-in
Capital
498,000,000 (NT$)
Location of Company
Taiwan
, Taichung City
Exit Status
Emerging Stock Exchange(2022)
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
The company has developed a series of first-in-human novel drugs that are based on the innovative technology platforms of “targeted exosome for drug delivery” and “trispecific T-cell engager antibody”. The Company has various technical patents for the exosomes and multi-specific antibody drugs. ShineOn collaborated with worldwide renown research institutes, international capable CDMO/CRO companies and professional expert consulting groups to create new biological drugs to treat patients with cancers. According to the Cortellis database, ShineOn is ranked among the top ten companies worldwide for developing "next-generation" targeted exosome therapeutic drugs and multi-specific antibody drugs.
The company was successfully listed on the Emerging Stock Market of Taipei Exchange (code 6926) in November 2022.
The company was successfully listed on the Emerging Stock Market of Taipei Exchange (code 6926) in November 2022.
The content above was translated by Ai
